FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1855278889> ?p ?o ?g. }

• W1855278889 endingPage "1476" @default.
• W1855278889 startingPage "1463" @default.
• W1855278889 abstract "The ability of short-acting insulin secretagogues to reduce the risk of diabetes or cardiovascular events in people with impaired glucose tolerance is unknown.In a double-blind, randomized clinical trial, we assigned 9306 participants with impaired glucose tolerance and either cardiovascular disease or cardiovascular risk factors to receive nateglinide (up to 60 mg three times daily) or placebo, in a 2-by-2 factorial design with valsartan or placebo, in addition to participation in a lifestyle modification program. We followed the participants for a median of 5.0 years for incident diabetes (and a median of 6.5 years for vital status). We evaluated the effect of nateglinide on the occurrence of three coprimary outcomes: the development of diabetes; a core cardiovascular outcome that was a composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure; and an extended cardiovascular outcome that was a composite of the individual components of the core composite cardiovascular outcome, hospitalization for unstable angina, or arterial revascularization.After adjustment for multiple testing, nateglinide, as compared with placebo, did not significantly reduce the cumulative incidence of diabetes (36% and 34%, respectively; hazard ratio, 1.07; 95% confidence interval [CI], 1.00 to 1.15; P=0.05), the core composite cardiovascular outcome (7.9% and 8.3%, respectively; hazard ratio, 0.94, 95% CI, 0.82 to 1.09; P=0.43), or the extended composite cardiovascular outcome (14.2% and 15.2%, respectively; hazard ratio, 0.93, 95% CI, 0.83 to 1.03; P=0.16). Nateglinide did, however, increase the risk of hypoglycemia.Among persons with impaired glucose tolerance and established cardiovascular disease or cardiovascular risk factors, assignment to nateglinide for 5 years did not reduce the incidence of diabetes or the coprimary composite cardiovascular outcomes. (ClinicalTrials.gov number, NCT00097786.)" @default.
• W1855278889 created "2016-06-24" @default.
• W1855278889 creator A5000630097 @default.
• W1855278889 creator A5004052675 @default.
• W1855278889 creator A5005350140 @default.
• W1855278889 creator A5010140902 @default.
• W1855278889 creator A5010481003 @default.
• W1855278889 creator A5013519955 @default.
• W1855278889 creator A5013844160 @default.
• W1855278889 creator A5016491875 @default.
• W1855278889 creator A5016666287 @default.
• W1855278889 creator A5017004610 @default.
• W1855278889 creator A5021022068 @default.
• W1855278889 creator A5021169264 @default.
• W1855278889 creator A5025169113 @default.
• W1855278889 creator A5027213857 @default.
• W1855278889 creator A5030736138 @default.
• W1855278889 creator A5033041702 @default.
• W1855278889 creator A5034671525 @default.
• W1855278889 creator A5034827753 @default.
• W1855278889 creator A5034967151 @default.
• W1855278889 creator A5036306321 @default.
• W1855278889 creator A5039186899 @default.
• W1855278889 creator A5039563874 @default.
• W1855278889 creator A5040182038 @default.
• W1855278889 creator A5041800929 @default.
• W1855278889 creator A5043026087 @default.
• W1855278889 creator A5046421112 @default.
• W1855278889 creator A5046628178 @default.
• W1855278889 creator A5047323233 @default.
• W1855278889 creator A5049740900 @default.
• W1855278889 creator A5050189058 @default.
• W1855278889 creator A5055509949 @default.
• W1855278889 creator A5056876628 @default.
• W1855278889 creator A5059264080 @default.
• W1855278889 creator A5060829829 @default.
• W1855278889 creator A5062468141 @default.
• W1855278889 creator A5065924611 @default.
• W1855278889 creator A5066700951 @default.
• W1855278889 creator A5069336249 @default.
• W1855278889 creator A5069551223 @default.
• W1855278889 creator A5072424638 @default.
• W1855278889 creator A5074200707 @default.
• W1855278889 creator A5074490785 @default.
• W1855278889 creator A5074958027 @default.
• W1855278889 creator A5078294568 @default.
• W1855278889 creator A5080414941 @default.
• W1855278889 creator A5081397975 @default.
• W1855278889 creator A5082530971 @default.
• W1855278889 creator A5084213619 @default.
• W1855278889 creator A5084440394 @default.
• W1855278889 creator A5084593004 @default.
• W1855278889 creator A5084771861 @default.
• W1855278889 creator A5086471934 @default.
• W1855278889 creator A5087708317 @default.
• W1855278889 creator A5089307547 @default.
• W1855278889 date "2010-04-22" @default.
• W1855278889 modified "2023-10-18" @default.
• W1855278889 title "Effect of Nateglinide on the Incidence of Diabetes and Cardiovascular Events" @default.
• W1855278889 cites W1511593276 @default.
• W1855278889 cites W1965055157 @default.
• W1855278889 cites W1967140460 @default.
• W1855278889 cites W1983269691 @default.
• W1855278889 cites W2009918956 @default.
• W1855278889 cites W2039454137 @default.
• W1855278889 cites W2042942731 @default.
• W1855278889 cites W2083342497 @default.
• W1855278889 cites W2089961600 @default.
• W1855278889 cites W2107732097 @default.
• W1855278889 cites W2115607452 @default.
• W1855278889 cites W2123744385 @default.
• W1855278889 cites W2134293572 @default.
• W1855278889 cites W2146536851 @default.
• W1855278889 cites W2154717294 @default.
• W1855278889 cites W2158822657 @default.
• W1855278889 cites W2332951586 @default.
• W1855278889 cites W4229984599 @default.
• W1855278889 cites W4233562854 @default.
• W1855278889 cites W4236105504 @default.
• W1855278889 cites W4241308027 @default.
• W1855278889 cites W4242589154 @default.
• W1855278889 cites W4253905022 @default.
• W1855278889 doi "https://doi.org/10.1056/nejmoa1001122" @default.
• W1855278889 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20228402" @default.
• W1855278889 hasPublicationYear "2010" @default.
• W1855278889 type Work @default.
• W1855278889 sameAs 1855278889 @default.
• W1855278889 citedByCount "418" @default.
• W1855278889 countsByYear W18552788892012 @default.
• W1855278889 countsByYear W18552788892013 @default.
• W1855278889 countsByYear W18552788892014 @default.
• W1855278889 countsByYear W18552788892015 @default.
• W1855278889 countsByYear W18552788892016 @default.
• W1855278889 countsByYear W18552788892017 @default.
• W1855278889 countsByYear W18552788892018 @default.
• W1855278889 countsByYear W18552788892019 @default.
• W1855278889 countsByYear W18552788892020 @default.
• W1855278889 countsByYear W18552788892021 @default.

• next